Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, discusses the management of post-transplant complications in patients with Hodgkin lymphoma (HL), and important factors to consider when patients are offered autologous transplantation. Dr Evens also highlights the use of brentuximab vedotin and checkpoint inhibitors for post-transplant maintenance therapy, and summarizes other considerations for high-risk patients. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Grant/Research Support: ORIEN and Leukemia & Lymphoma Society, Advisory Board (Research Related): Seattle Genetics, Hutchmed, Incyte, Daiichi Sankyo, and Epizyme Consultant (Educational Related): Research to Practice, Curio, Cota, Patient Power, Curio Science, and OncLive Consultant (Data and Safety Monitoring Board): Novartis, Abbvie, and Pharmacyclics